ClinicalTrials.gg
Not yet recruitingNCT05953506Updated Jul 20, 2023

Phase 1a Study in Healthy Participants

A Phase 1 interventional study of HS-10506 and HS-10506 Placebo in Healthy, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-20.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral HS-10506 in Chinese Healthy Subjects.

Read the detailed description

This is a phase 1a, first-in-human, double-blind, placebo-controlled clinical trial. The primary objective is to assess the safety, tolerability and pharmacokinetic of single dose HS-10506 in healthy subjects. The secondary objective is to observed pharmacokinetic parameters and metabolites after single dose of HS-10506.

02

Conditions studied

  • Healthy

Keywords

  • HS-10506, Phase 1, Healthy
03

In context

Lead sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd. is the lead sponsor of 138 studies on the registry; 72 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy participants aged from 18 to 45 years
  • Subjects need to fully understand the research content and process, as well as possible adverse reactions, and voluntarily signed Form
  • Males' weight ≥ 50kg, females' weight ≥ 45kg, {BMI, BMI=weight/height 2 (kg/m2)} is controlled within the range of 18\~28 (including the critical value)
  • During the study and for 3 months after receiving the last dose of study drug, subjects must agree not to donate sperm or eggs, not to plan to have children, and to use an effective method of

Exclusion criteria

Exclusion Criteria:

  • Has a history of chronic or serious disease from neuropsychiatric system, cardiovascular system, urinary system, digestive system, respiratory system, skeletal muscle system, metabolic endocrine system, skin disease, blood system, immune system or tumor
  • Has taken any drugs, including prescription drugs, over-the-counter drugs, herbal preparations, some health products or inhibitor/inducer of or CYP3A5, within 2 weeks (or 5 half-lives) before screening and throughout the study period
  • Has abnormalities, such as corrected according to Fridericia formula(QTcF), >450 ms (males), >470 ms (females)
  • Has current manifestation of blood pressure or pulse abnormalities in resting state: such as systolic blood pressure \<90 mmHg or ≥140 mmHg, diastolic blood pressure \<60 mmHg or ≥90 mmHg, pulse \<55 bpm or >100 bpm
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    HS-10506

    Healthy participants will be enrolled in dose escalation cohorts. Healthy participants will be receive either HS-10506 or matching placebo on Day 1.

    Drug: HS-10506

  • Experimental
    HS-10506 Placebo

    Healthy participants will be enrolled in dose escalation cohorts. Healthy participants will be receive either HS-10506 or matching placebo on Day 1.

    Drug: HS-10506 Placebo

Interventions

  • HS-10506 will be administered orally once on Day 1.

  • DrugHS-10506 Placebo

    Matching placebo will be administered orally once on Day 1.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AEs), serious adverse events (SAEs) and adverse events leading to discontinuation from the study, and their correlation with the investigational drug

    The definition of adverse event \[AE\] is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The definition of serious adverse event \[SAE\] is any untoward medical occurrence at any dose that results in death; is life threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; results in congenital anomaly/birth defect.

    Time frame: Screening until Trail phase (up to 5 weeks)

  2. Number of participants with clinically significant change from baseline in vital signs

    Time frame: From baseline to Day 3

  3. Number of participants with clinically significant abnormalities in physical examination

    Time frame: From baseline to Day 3

  4. Changes in 12-lead electrocardiogram from before to after dosing

    Descriptive statistics of heart rate, PR interval, QT interval, and QTcF for observed values and changes from baseline will be summarized at each scheduled time point.

    Time frame: From baseline to Day 3

  5. Change in Stanford Sleepiness Scale score from before to after dosing

    Stanford Sleepiness Scale(SSS) is a simple and accurate method used to assess sleepiness symptom. Respondents use the scale from 1 to 7 to indicate their current level of sleepiness. Higher scores mean a higher level of sleepiness. Descriptive statistics of SSS scores and changes from baseline will be summarized at each scheduled time point.

    Time frame: From baseline to 4 hours after dosing

Secondary outcomes

  1. Observed maximum plasma concentration (Cmax)

    Cmax will be obtained following administration of a single oral dose of HS-10506.

    Time frame: up to 48 hours after dosing

  2. Time to reach maximum plasma concentration (Tmax)

    Tmax will be obtained following administration of a single oral dose of HS-10506.

    Time frame: up to 48 hours after dosing

  3. Area under the concentration-time curve from time zero to last time of quantifiable concentration(AUC0-t)

    Area under the concentration-time curve from time zero to last time of quantifiable concentration(AUC0-t)will be obtained following administration of a single oral dose of HS-10506.

    Time frame: up to 48 hours after dosing

  4. Area under the concentration-time curve from time zero to infinity(AUC0-∞)

    AUC0-t will be obtained following administration of a single oral dose of HS-10506.

    Time frame: up to 48 hours after dosing

  5. Terminal Rate Constant(λz)

    Terminal Rate Constant(λz) will be obtained following administration of a single oral dose of HS-10506.

    Time frame: up to 48 hours after dosing

  6. Elimination Halflife (T1/2)

    Elimination Halflife (T1/2) is the time measured for the concentration to decrease by one half,which will be obtained following administration of a single oral dose of HS-10506.

    Time frame: up to 48 hours after dosing

  7. Apparent clearance(CL/F)

    CL/F will be obtained following administration of a single oral dose of HS-10506.

    Time frame: up to 48 hours after dosing

  8. Apparent Volume of Distribution(Vd/F)

    Vd/F will be obtained following administration of a single oral dose of HS-10506. Time Frame: up to 48 hours after dosing

    Time frame: up to 48 hours after dosing

  9. Mean Residence Time(MRT)

    RT will be obtained following administration of a single oral dose of HS-10506.

    Time frame: up to 48 hours after dosing

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2023; primary completion for Dec 2023, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2023
First posted
Jul 20, 2023
StartEst.
Jul 17, 2023
Primary completionEst.
Dec 24, 2023
CompletionEst.
Dec 24, 2023
Last update
Jul 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05953506
Responsible party
Sponsor
First posted
Jul 20, 2023
Start date
Jul 17, 2023 (estimated)
Primary completion
Dec 24, 2023 (estimated)
Completion
Dec 24, 2023 (estimated)
Last update
Jul 20, 2023

Study contacts

Huafang Li
Contact
lhlh_5@163.com
021-34773128

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HS-10506

Start the discussion